San Antonio-based BioAffinity’s CyPath Lung, a non-invasive flow cytometry diagnostic test for lung cancer, is set to be used in the partnership to analyze the at-home collection of sputum, according to a news release.
Patients are slated to collect their samples at home with Smiths Medical’s Acapella device before shipping them overnight to the laboratory where the CyPath Lung, a laboratory-developed test licensed and developed by Precision Pathology Services, will profile the lung micro-environment, including the presence of cancer-associated cells, and provide results to the physician within minutes.
“The partnership enables the use of the Acapella vibratory PEP therapy system made by Smiths Medical for at-home collection of samples that are analyzed by BioAffinity’s CyPath Lung, a patient-friendly test shown to have high sensitivity and specificity in detecting lung cancer in people at high risk for the disease,” BioAffinity Technologies president & CEO Maria Zannes said in the release. “One of the hallmarks of CyPath Lung is the ease by which patients collect their sputum samples at home using the Acapella device.”
“Innovation is a cornerstone of Smiths Medical. As a leader in airway management solutions, we are proud that our Acapella device can facilitate the use of this non-invasive breakthrough test that can detect lung cancer at its earliest stages when treatment can be most effective and lives can be saved,” added Smiths Medical CEO JehanZeb Noor. “Smiths Medical and BioAffinity Technologies share a commitment to putting patients first and making quality healthcare accessible and affordable.”